Expert Interview
A Third Look: Discussing the potential of AbbVie and Cerevel's Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM) for Schizophrenia
Ticker(s): ABBVInstitution: UCLA School of Medicine
- Double board certified pyschiatric physician in adult and child psychiatry
- Received medical degree from Texas Tech University Health Sciences Center at Lubbock and has been in practice between 6-10 years
- treats 65 patients for Schizophrenia per month and 80 patients with bipolar I/II per month
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
